Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.80)
# 419
Out of 4,362 analysts
469
Total ratings
57.5%
Success rate
17.9%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Reiterated: Buy | $52 → $37 | $36.21 | +2.87% | 33 | Jun 3, 2026 | |
| ALT Altimmune | Maintained: Buy | n/a | $2.87 | - | 3 | May 29, 2026 | |
| IVA Inventiva | Reiterated: Buy | n/a | $4.04 | - | 3 | May 29, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $709 → $514 | $488.15 | +5.21% | 13 | May 26, 2026 | |
| ABCL AbCellera Biologics | Reiterated: Buy | $12 | $5.72 | +109.79% | 12 | May 22, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,281 | $1,078.78 | +18.75% | 34 | May 21, 2026 | |
| KROS Keros Therapeutics | Maintained: Buy | n/a | $10.50 | - | 21 | May 15, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $70 | $30.05 | +132.95% | 7 | May 11, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Buy | n/a | $32.11 | - | 2 | May 8, 2026 | |
| ABSI Absci | Reiterated: Buy | $11 | $5.94 | +85.19% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $106 | $70.71 | +49.91% | 37 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $54.72 | - | 21 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $7.70 | +29.87% | 15 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $73.21 | - | 21 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $97.98 | - | 33 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $95.41 | - | 20 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.50 | - | 7 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $30.63 | - | 5 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.50 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $44.64 | - | 29 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $338.22 | - | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $103.86 | +106.05% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $15.48 | +48.58% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $618.95 | +31.19% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $91.37 | -8.07% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.47 | - | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $195.96 | -27.54% | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.30 | - | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $114.70 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.34 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $217.13 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.03 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $51.87 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $3.62 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.000001 | n/a | 7 | Mar 20, 2023 |
Edgewise Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $52 → $37
Current: $36.21
Upside: +2.87%
Altimmune
May 29, 2026
Maintained: Buy
Price Target: n/a
Current: $2.87
Upside: -
Inventiva
May 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.04
Upside: -
Madrigal Pharmaceuticals
May 26, 2026
Reiterated: Buy
Price Target: $709 → $514
Current: $488.15
Upside: +5.21%
AbCellera Biologics
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $5.72
Upside: +109.79%
Eli Lilly and Company
May 21, 2026
Maintained: Buy
Price Target: $1,281
Current: $1,078.78
Upside: +18.75%
Keros Therapeutics
May 15, 2026
Maintained: Buy
Price Target: n/a
Current: $10.50
Upside: -
MBX Biosciences
May 11, 2026
Maintained: Buy
Price Target: $70
Current: $30.05
Upside: +132.95%
NewAmsterdam Pharma Company
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $32.11
Upside: -
Absci
May 8, 2026
Reiterated: Buy
Price Target: $11
Current: $5.94
Upside: +85.19%
May 6, 2026
Reiterated: Buy
Price Target: $106
Current: $70.71
Upside: +49.91%
May 1, 2026
Maintained: Buy
Price Target: n/a
Current: $54.72
Upside: -
May 1, 2026
Maintained: Hold
Price Target: $10
Current: $7.70
Upside: +29.87%
May 1, 2026
Maintained: Buy
Price Target: n/a
Current: $73.21
Upside: -
Apr 29, 2026
Reiterated: Hold
Price Target: n/a
Current: $97.98
Upside: -
Apr 29, 2026
Maintained: Buy
Price Target: n/a
Current: $95.41
Upside: -
Apr 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.50
Upside: -
Apr 20, 2026
Maintained: Buy
Price Target: n/a
Current: $30.63
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.50
Upside: -
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $44.64
Upside: -
Nov 5, 2025
Maintained: Hold
Price Target: n/a
Current: $338.22
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $103.86
Upside: +106.05%
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $15.48
Upside: +48.58%
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $618.95
Upside: +31.19%
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $91.37
Upside: -8.07%
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.47
Upside: -
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $195.96
Upside: -27.54%
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $1.30
Upside: -
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $114.70
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $25.34
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $217.13
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $2.03
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $51.87
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $3.62
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.000001
Upside: n/a